BIOTEK 2021 Funding Success 4.000.000 NOK
AlgiPharma together with FMC Biopolymer and SINTEF are part of the award winning research consortium co-ordinated by Dr. Gudmund Skjaak-Braek at the Norwegian National Biotechnology Institute (NTNU).
This author has not written his bio yet.
But we are proud to say that rogerhenriksen contributed 22 entries already.
AlgiPharma together with FMC Biopolymer and SINTEF are part of the award winning research consortium co-ordinated by Dr. Gudmund Skjaak-Braek at the Norwegian National Biotechnology Institute (NTNU).
Khan S, Tøndervik A, Sletta H, Klinkenberg G, Emanuel C, Onsøyen E, Myrvold R, Howe RA, Walsh TR, Hill KE, Thomas DW. Antimicrob Agents Chemother. 2012 Oct;56(10):5134-41. doi: 10.1128/AAC.00525-12. Epub 2012 Jul 23. External link to Pubmed.gov Abstract The uncontrolled, often inappropriate use of antibiotics has resulted in the increasing prevalence of antibiotic-resistant pathogens, with […]
Philip Rye (1962) came to AlgiPharma in 2012. Astrid Hilde Myrset (1956) is a biochemist by training, and joined AlgiPharma in 2012.
AlgiPharma has together with partners Smerud Medical Research and Simbec Research been awarded a EUROSTARS grant for a €4,6 million project.
AlgiPharma has received a research grant from CFF, the Cystic Fibrosis Foundation, to perform an in-vitro study of its proposed cystic fibrosis medicine.
AlgiPharma has been granted permission to start its clinical phase 2 trial in cystic fibrosis patients by the Irish Medicines Board. The study title is: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (Oligo-G) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa.
AlgiPharma has together with Prof. Chandan Sen, at Ohio State University embarked on a study to investigate the effects of OligoG in a unique biofilm infected in vivo wound healing model.
Oligo-G CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. All adverse events monitored were mild and transient. No serious adverse events, no deaths, no discontinuations.
A clinical phase I for AlgiPharma’s prospective medicine for Cystic Fibrosis (respiratory diseases), Oligo-G CF-5/20, was approved by the Medicines and Healthcare Product Regulatory Agency, MRHA, and is initiated at SIMBEC (UK) and scheduled to be concluded before the end of the year. Results are set to be reported in the first quarter of 2010.
The Research Council of Norway (Norges Forskningsråd (NFR)) has awarded AlgiPharma grants for two new projects “Biofilm” and “Epipharm II” representing a continuation and expansion of the NFR support for AlgiPharma’s alginate oligomer research efforts. These grants are administered under the NFR program for User directed Innovation Arena.
AlgiPharma AS
Industriveien 33
N-1337 Sandvika
Norway
Mail: post@algipharma.com